Rigel Pharmaceuticals, Inc. (RIGL)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
32.43 USD
+0.66
(2.077%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 32.43 Short-term: ★★★☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 4:02 p.m. EDT
RIGL is showing mixed signals for both short-term and long-term investors. The recent price action has been volatile, with the stock trading near its 52-week low, but there are signs of potential support at key levels. The options activity suggests a mix of bullish and bearish sentiment, with a notable volume spike at certain strike prices. While the stock may present a buying opportunity for short-term traders looking to capitalize on potential momentum, long-term investors should be cautious given the high overall risk and lack of dividend history. The recent positive analyst coverage and earnings reports may provide some support, but the stock's fundamentals and valuation metrics suggest it is not a strong long-term hold. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.179521 |
| AutoETS | 0.193120 |
| AutoARIMA | 0.193121 |
| AutoTheta | 0.230078 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 22.95 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.094 |
| Excess Kurtosis | -1.58 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 13.616 |
| Revenue per Share | 16.361 |
| Market Cap | 599,307,072 |
| Trailing P/E | 1.66 |
| Forward P/E | 6.76 |
| Beta | 1.27 |
| Profit Margins | 124.72% |
| Website | https://www.rigel.com |
As of April 11, 2026, 4:02 p.m. EDT: Options speculators are showing mixed signals. The calls for the June 18 expiration show a significant volume spike and major OI wall at the 37.0 strike, indicating potential bullish sentiment. However, the puts for the June 18 expiration also show a volume spike at the 25.0 strike, suggesting some bearish positioning. The overall IV levels are relatively high, indicating increased volatility expectations. The ATM anchor strikes are showing mixed IV levels, which could imply uncertainty about the immediate direction of the stock.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.9155345 |
| Address1 | 611 Gateway Boulevard |
| Address2 | Suite 900 |
| All Time High | 1,147.5 |
| All Time Low | 6.4 |
| Ask | 32.62 |
| Ask Size | 1 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 412,260 |
| Average Daily Volume3 Month | 350,296 |
| Average Volume | 350,296 |
| Average Volume10Days | 412,260 |
| Beta | 1.267 |
| Bid | 32.26 |
| Bid Size | 1 |
| Board Risk | 3 |
| Book Value | 21.38 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 32.43 |
| Current Ratio | 2.42 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 33.17 |
| Day Low | 32.0101 |
| Debt To Equity | 13.616 |
| Display Name | Rigel Pharmaceuticals |
| Earnings Call Timestamp End | 1,772,573,400 |
| Earnings Call Timestamp Start | 1,772,573,400 |
| Earnings Growth | 15.987 |
| Earnings Quarterly Growth | 17.692 |
| Earnings Timestamp | 1,772,571,600 |
| Earnings Timestamp End | 1,778,011,200 |
| Earnings Timestamp Start | 1,778,011,200 |
| Ebitda | 127,881,000 |
| Ebitda Margins | 0.43455002 |
| Enterprise To Ebitda | 3.89 |
| Enterprise To Revenue | 1.69 |
| Enterprise Value | 497,431,616 |
| Eps Current Year | 4.79928 |
| Eps Forward | 4.79619 |
| Eps Trailing Twelve Months | 19.48 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 650 624 1101 |
| Fifty Day Average | 30.4306 |
| Fifty Day Average Change | 1.9994011 |
| Fifty Day Average Change Percent | 0.06570364 |
| Fifty Two Week Change Percent | 91.55345 |
| Fifty Two Week High | 52.24 |
| Fifty Two Week High Change | -19.810001 |
| Fifty Two Week High Change Percent | -0.37921134 |
| Fifty Two Week Low | 16.43 |
| Fifty Two Week Low Change | 16.0 |
| Fifty Two Week Low Change Percent | 0.9738283 |
| Fifty Two Week Range | 16.43 - 52.24 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 975,508,200,000 |
| Float Shares | 18,167,030 |
| Forward Eps | 4.79619 |
| Forward P E | 6.761617 |
| Free Cashflow | 74,607,248 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 172 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.82018995 |
| Gross Profits | 241,366,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03068 |
| Held Percent Institutions | 0.90121 |
| Implied Shares Outstanding | 18,480,019 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://ir.rigel.com/phoenix.zhtml?c=120936&p=irol-irhome |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,719,446,400 |
| Last Split Factor | 1:10 |
| Long Business Summary | Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California. |
| Long Name | Rigel Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 599,307,072 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_33851 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 367,024,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 599,307,016 |
| Number Of Analyst Opinions | 5 |
| Open | 32.8 |
| Operating Cashflow | 75,655,000 |
| Operating Margins | 0.33194 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Phone | 650 624 1100 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 32.43 |
| Post Market Time | 1,776,456,605 |
| Previous Close | 31.77 |
| Price Eps Current Year | 6.757263 |
| Price Hint | 2 |
| Price To Book | 1.5168382 |
| Price To Sales Trailing12 Months | 2.0365062 |
| Profit Margins | 1.24718 |
| Quick Ratio | 2.083 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.66 |
| Regular Market Change Percent | 2.07743 |
| Regular Market Day High | 33.17 |
| Regular Market Day Low | 32.0101 |
| Regular Market Day Range | 32.0101 - 33.17 |
| Regular Market Open | 32.8 |
| Regular Market Previous Close | 31.77 |
| Regular Market Price | 32.43 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 416,426 |
| Return On Assets | 0.23146 |
| Return On Equity | 1.85944 |
| Revenue Growth | 0.212 |
| Revenue Per Share | 16.361 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 18,480,019 |
| Shares Percent Shares Out | 0.2062 |
| Shares Short | 3,810,645 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 3,752,643 |
| Short Name | Rigel Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.21180001 |
| Short Ratio | 10.22 |
| Source Interval | 15 |
| State | CA |
| Symbol | RIGL |
| Target High Price | 71.0 |
| Target Low Price | 38.0 |
| Target Mean Price | 51.2 |
| Target Median Price | 50.0 |
| Total Cash | 154,955,008 |
| Total Cash Per Share | 8.388 |
| Total Debt | 53,303,000 |
| Total Revenue | 294,281,984 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 19.48 |
| Trailing P E | 1.6647844 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 33.5821 |
| Two Hundred Day Average Change | -1.1520996 |
| Two Hundred Day Average Change Percent | -0.034306955 |
| Type Disp | Equity |
| Volume | 416,426 |
| Website | https://www.rigel.com |
| Zip | 94,080 |